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ABSTRACT
Objective: Vaccine against human papillomavirus
(HPV) has been offered free of charge to all 12-year-
old girls in Norway since 2009. Nevertheless, the
uptake of HPV vaccine is lower than for other
childhood vaccines. The aim of this study was to
examine whether parental education and income are
associated with initiation and completion of HPV
vaccination.
Design: Nationwide register-based study.
Setting: Publicly funded childhood immunisation
programme in Norway.
Participants: 91 405 girls born between 1997 and
1999 and registered in the Norwegian Central
Population Registry were offered HPV vaccine during
the first 3 programme years. Of these, 84 139 had
complete information on all variables and were
included in the study.
Measurements: Information on HPV-vaccination
status was obtained from the Norwegian Immunisation
Registry. Data on socioeconomic factors were extracted
from Statistics Norway. Risk differences (RDs) and CIs
were estimated with Poisson regression.
Results: In the study sample, 78.3% received at least
one dose of HPV vaccine and 73.6% received all three
doses. High maternal education was significantly
associated with lower probability of initiating HPV
vaccination (multivariable RD=−5.5% (95% CI −7.0%
to −4.0%) for highest compared with lowest education
level). In contrast, high maternal income was
significantly associated with higher probability of
initiating vaccination (multivariable RD=10.1% (95% CI
9.0% to 11.3%) for highest compared with lowest
quintile). Paternal education and income showed
similar, but weaker, associations. The negative
association between education and initiation was only
seen for incomes below the median value.
Conclusions: In spite of the presumably equal access
to HPV vaccine in Norway, we found socioeconomic
disparities in vaccine uptake. More studies are needed
to explain the underlying factors responsible for the
observed socioeconomic differences. Insight into these
factors is necessary to target information and increase
vaccination coverage to ultimately reduce HPV-related
disease across socioeconomic barriers.
INTRODUCTION
Vaccine against human papillomavirus
(HPV) was introduced in the Norwegian
Childhood Immunisation Programme in
2009. The vaccine is offered through a
school-based programme to all 12-year-old
girls. The aim is to provide cervical cancer
protection to all women and thereby over-
come potential socioeconomic differences in
cervical cancer incidence. About 50% of cer-
vical cancer cases in Norway arise from the
20% of the population who, for different
reasons, do not attend screening.1
Strengths and limitations of this study
▪ The strengths of this study include a large
sample size. The study is nationwide and
includes all girls offered vaccination against
human papillomavirus (HPV) during the first
3 years of the publicly funded HPV immunisation
programme in Norway.
▪ Individual data on vaccination and socio-
economic factors from different national regis-
tries, covering the entire Norwegian population,
were linked. This allowed us to study the asso-
ciations of maternal and paternal education, and
income, with the uptake of HPV vaccine, while
controlling for numerous possible confounders.
▪ Missing information on parental education and
income was disproportionately distributed, with
more missing numbers for immigrant parents.
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The Norwegian healthcare system is built on the prin-
ciple of equal access to service for all citizens, reﬂected
in the delivery of vaccines in the Childhood
Immunisation Programme. All vaccines in the pro-
gramme, including the HPV vaccine, are offered free of
charge within the public health service. The HPV
vaccine is given at school, during school hours, by public
health nurses, without parents present. Thus, there are
no obvious barriers to vaccination, such as cost or access
to the programme.
Vaccination coverage is well above 90% for all vaccines
in the programme provided during the ﬁrst 2 years of
life. Furthermore, the proportion of 16-year-olds in 2013
(born 1997) who had received all recommended doses,
including school age boosters, was 91% for diphtheria
vaccine and 94% for vaccine against polio, measles,
mumps and rubella.2 The uptake of HPV vaccine has,
however, not yet reached the same level as the other
childhood vaccines.3 In spite of the presumably equal
access to HPV vaccine in Norway, we speculate that
socioeconomic disparities in vaccine uptake may still
exist. The association between socioeconomic factors
and vaccine uptake has not earlier been studied in
Norway.
Associations between deprivation and uptake of HPV
vaccine have previously been investigated in other coun-
tries with publicly funded immunisation programmes.4–9
However, these studies have used aggregates of socio-
economic conditions such as deprivation indices based
on postcodes of residence, and results are inconsistent.
Population based studies with individual data on socio-
economic factors are few. Moreover, to the best of our
knowledge, no previous studies have aimed to assess the
associations between speciﬁc socioeconomic factors,
such as education and income, and the uptake of HPV
vaccine. Furthermore, the differential associations of
maternal versus paternal education and income are
unknown.
We had the unique opportunity to link individual data
from several national sources: The Norwegian Central
Population Registry, Statistics Norway and the Norwegian
Immunisation Registry. This allowed us to estimate the
association between speciﬁc socioeconomic measures,
namely maternal and paternal education and income,
and initiation and completion of HPV vaccination, while
controlling for a number of possible confounders, in a
large cohort comprising all girls offered the HPV
vaccine during the 3 ﬁrst years of the HPV vaccination
programme in Norway.
METHODS
HPV vaccination programme
The HPV vaccine is offered free of charge in a three-
dose schedule to 12-year-old girls during seventh grade.
Parents provide consent to vaccination, usually by return-
ing a signed informed consent form to the school nurse.
Although the girls do not consent to HPV vaccination
themselves, the parents are encouraged to discuss with
their daughters and take their views into consideration
when deciding whether to consent to HPV vaccination.
Each programme year corresponds to an academic year,
starting 20 August and ending 20 June the following
year. Programme years 1, 2 and 3 included girls born in
1997, 1998 and 1999, respectively. In addition, due to
the coinciding of the start of the HPV vaccination pro-
gramme and the H1N1 inﬂuenza pandemic in the
autumn of 2009, girls born in 1997 were also offered the
vaccine during programme year 2.
Data sources
The Norwegian Central Population Registry was used to
deﬁne the study population, namely all girls born
between 1997 and 1999, residing in Norway as of 31
December 2012, or previously. Information on emigra-
tion, immigration or death was also obtained from the
Norwegian Central Population Registry.
Dates of HPV vaccinations were extracted from the
Norwegian Immunisation Registry on 22 August 2013.
Notiﬁcation to the Norwegian Immunisation Registry of
all vaccinations within the childhood immunisation pro-
gramme is mandatory and does not require consent
from either the vaccinated child or the parents. The
transfer of data is electronic from the electronic patient
journal to the register, thus the register is continuously
updated.10
Information on maternal and paternal highest
attained education level (as of 31 December 2012),
maternal and paternal income in 2011, maternal and
paternal employment status in 2012, municipality and
county of residence (as of 31 December 2012), country
of birth of the girls and their parents, number of siblings
and maternal age at birth of daughter, was retrieved
from Statistics Norway and includes data from the
National Education Data Base and the National Tax
Registry. The data in the National Education Database is
compiled by Statistics Norway, and is based on informa-
tion from all schools and institutions of higher educa-
tion in Norway. Information on education completed
abroad is obtained from the Norwegian State
Educational Loan Fund and the Health Personnel
Register, as well as from surveys among immigrants per-
formed by Statistics Norway, the latest in 2011–2012. The
data in the Tax Registry are obtained by Statistics
Norway from The Directorate of Taxes. The data from
Statistics Norway are updated yearly.
The unique identiﬁcation number allocated to all
Norwegian residents was used to link the national
registries.
Outcome variables
The main outcome variable was initiation of HPV vaccin-
ation, deﬁned as receipt of at least one dose.
The secondary outcome variable was completion of the
HPV-vaccination series, deﬁned as receipt of all three
doses with time intervals of at least 30 days between the
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ﬁrst and second dose, and at least 90 days between the
second and third dose, in accordance with the
minimum intervals speciﬁed in the Summary of Product
Characteristics (SPC) for Gardasil, the vaccine used in
Norway. No restrictions on maximum intervals between
the doses were applied.
Main exposure variables
Maternal and paternal levels of education were categorised
in ﬁve groupings: compulsory education (comprising
primary and lower secondary education, ≤10 years of
schooling), upper secondary levels 1 and 2 (11–12 years
of schooling), completed upper secondary education
(including tertiary vocational education, 13–14 years of
schooling), higher education, undergraduate level (14–
17 years of schooling) and higher education, graduate
level (≥18 years of schooling).11
Maternal and paternal incomes were each divided into
quintiles.
Other covariates
Maternal and paternal employment status was categorised as
‘employed’ (including self-employed) or ‘unemployed’
(including those outside the labour force and those
within the labour force who were unemployed).
Country of origin was deﬁned as ‘Norway’ for girls with
at least one Norwegian-born parent. Otherwise, country
of origin was deﬁned as the girl’s country of birth if she
was foreign born, or as her mother’s country of birth if
the girl was born in Norway. Countries of origin other
than Norway were grouped into the following categories:
Western Europe, Eastern Europe (including former
Soviet Republics), Middle East/North Africa, South Asia,
East/Southeast Asia, sub-Saharan Africa and America/
Oceania (see online supplementary table S1 for list of
countries in each category).
Municipality of residence was categorised according to
number of inhabitants: rural (<10 000 inhabitants),
semiurban (10 000–49 999 inhabitants) and urban
(≥50 000 inhabitants).
Maternal age at birth of daughter was categorised as ≤25,
26–30, 31–35 and ≥36 years.
Number of siblings was categorised as 0, 1, 2, 3 and ≥4.
Study sample
A total of 96 692 girls born between 1997 and 1999 were
registered in the Norwegian Central Population Registry
(ﬁgure 1). Dates of immigration, emigration and death
were used to determine residency in Norway. Girls who
were not residents of Norway during the entire pro-
gramme year in which their birth cohort was offered
HPV vaccination were excluded. A total of 91 405 girls
were considered eligible for vaccination in the period.
We excluded 7266 girls with missing information on
maternal or paternal education, income or employment
status, or county of residence (ﬁgure 1). The remaining
84 139 girls had complete information on all variables,
and were included in analyses with initiation of HPV
vaccination as the outcome. Siblings (8.9% of the study
sample) were not excluded, since earlier studies have
found number of siblings and maternal age at birth of
daughter to be associated with HPV vaccination.12 13 In
analyses with completion of HPV-vaccination as the
outcome, girls who did not initiate vaccination were
excluded, leaving 65 843 girls for analyses.
Statistical analysis
We used Poisson regression to estimate risk differences
(RDs) and CIs.14 To account for correlation between sib-
lings, we used a robust variance estimator for cluster-
correlated data where each cluster contained girls with
the same mother.15 The maternal multivariable model
(model 1) included maternal education, income and
employment status, country of origin, urbanity, maternal
age at birth of daughter, number of siblings, county of
residence and year of birth. In the paternal model
(model 2) we removed maternal education, income and
employment status, and included paternal education,
income and employment status. The covariates other
than the main exposures were included because they
have previously been reported to be associated with
uptake of HPV vaccine.12 We used a Wald test to
examine whether the coefﬁcients corresponding to a
main variable were simultaneously equal to zero. We
examined whether income modiﬁed the effect of educa-
tion, by including interaction terms between education
and income (categorised as below or above median
income). The interaction terms were evaluated with a
Figure 1 Flow diagram of the study population.
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Wald test. The same models were used for both initi-
ation and completion of the HPV vaccination schedule
as outcomes.
All tests were two sided, and p<0.05 were considered
statistically signiﬁcant. The data were analysed with Stata/
SE V.12.1 (StataCorp, College Station, Texas, USA).
RESULTS
Of the 84 139 girls in the study sample, 78.3% initiated
HPV vaccination (table 1). Among those who initiated
vaccination, 94.1% completed the vaccination series,
resulting in a vaccine uptake with three doses of 73.6%.
Initiation of HPV vaccination increased from 71.8%
among girls in the 1997 birth cohort to 82.6% among
girls born in 1999.
The proportion of girls with mothers in the highest
education level was 7.8%, whereas 10.9% of the girls had
fathers in the highest education level (table 1). Median
maternal and paternal income was NOK 396 149 and
NOK 525 861, respectively. The proportion of girls with
employed mothers was 84.9%, while 89.2% had
employed fathers.
Initiation of HPV-vaccination
Girls with mothers in the highest education category
were signiﬁcantly less likely to initiate HPV vaccination
as compared to girls whose mothers had only compul-
sory education (table 2). The difference was small, but
when adjusting for maternal income and employment
status, country of origin, urbanity, maternal age at birth
of daughter, number of siblings, county of residence
and year of birth, the association was strengthened,
RD=−5.5% (95% CI−7.0% to −4.0%), and a clear nega-
tive trend was observed.
The proportion of girls initiating vaccination increased
with increasing maternal income, from 73.1% in the
lowest to 80.3% in the highest income quintile (table 2).
The association became stronger after adjustment, and
girls with mothers in the highest income quintile had
10.1 percentage points higher probability (95% CI 9.0%
to 11.3%) of initiating HPV vaccination as compared to
daughters of mothers in the lowest quintile.
Paternal education and income followed patterns
similar to maternal education and income, although the
associations were weaker and the differences between
the groups were smaller (table 2). In the multivariable
analysis, having a father with higher education was
associated with lower probability of initiating vaccination,
multivariable RD=−1.4% (95% CI −2.6% to −0.1%)
for highest compared with lowest education level.
Furthermore, girls with fathers in the highest income
quintile had 3.9 percentage points higher probability
(95% CI 2.8% to 5.0%) of initiating vaccination as com-
pared to daughters of fathers in the lowest quintile.
We found signiﬁcant interaction between maternal
education and income, pinteraction<0.0001 (table 3). High
education was negatively associated with initiation of
HPV vaccination only in girls whose mothers had
income below median value, multivariable RD=−11.4%
(95% CI −14.7% to −8.0%) for highest compared with
lowest education level. Signiﬁcant interaction was also
found between paternal education and income,
pinteraction=0.0004, and the association between initiation
Table 1 Characteristics of the study sample, N=84 139
n (%)
Vaccine uptake
Initiated HPV vaccination 65 843 (78.3)
Completed HPV vaccination 61 951 (73.6)
Maternal education (years of schooling)
Compulsory (≤10) 14 803 (17.6)
Upper secondary, levels 1 and 2 (11–12) 6669 (7.9)
Upper secondary, completed (13–14) 26 755 (31.8)
Higher, undergraduate level (14–17) 29 352 (34.9)
Higher, graduate level (≥18) 6560 (7.8)
Maternal income (NOK*), median 396 149
Maternal employment status
Employed 71 467 (84.9)
Unemployed 12 672 (15.1)
Paternal education (years of schooling)
Compulsory (≤10) 15 716 (18.7)
Upper secondary, levels 1 and 2 (11–12) 6234 (7.4)
Upper secondary, completed (13–14) 34 564 (41.1)
Higher, undergraduate level (14–17) 18 493 (22.0)
Higher, graduate level (≥18) 9132 (10.9)
Paternal income (NOK*), median 525 861
Paternal employment status
Employed 75 076 (89.2)
Unemployed 9 063 (10.8)
Country of origin†
Norway 77 683 (92.3)
Western Europe 695 (0.8)
Eastern Europe 1 258 (1.5)
Middle East/North Africa 1 417 (1.7)
South Asia 1 426 (1.7)
East/Southeast Asia 689 (0.8)
Sub-Saharan Africa 793 (0.9)
America/Oceania 178 (0.2)
Urbanity
Rural (<10 000 inhabitants) 20 772 (24.7)
Semiurban (10 000–49 999 inhabitants) 35 766 (42.5)
Urban (≥50 000 inhabitants) 27 601 (32.8)
Maternal age at birth of daughter (years)
≤25 18 822 (22.4)
26–30 31 553 (37.5)
31–35 23 967 (28.5)
>35 9 797 (11.6)
Number of siblings
0 3 076 (3.7)
1 30 811 (36.6)
2 30 507 (36.3)
3 12 122 (14.4)
≥4 7623 (9.1)
*NOK=Norwegian kroner (€1 EUR≈8.5 NOK).
†List of countries in each category is supplied in the
supplementary table S1.
HPV, human papillomavirus.
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of HPV vaccination and education was only observed if
the father had below median income, multivariable RD=
−5.4% (95% CI −8.0% to −2.9%) for highest compared
with lowest education level.
Mutual adjustment for maternal and paternal educa-
tion, income and employment status did not change the
results (not shown).
Completion of HPV vaccination
We observed weak, but statistically signiﬁcant positive
associations between maternal and paternal education
and income, and completion of the three-dose vaccin-
ation series in the univariable analyses (table 4). After
adjustment, only the association with paternal income
remained signiﬁcant.
No interaction was found between maternal education
and income (pinteraction=0.59), or between paternal edu-
cation and income (pinteraction=0.97).
Mutual adjustment for maternal and paternal educa-
tion, income and employment status did not change the
results (not shown).
DISCUSSION
We have assessed parents’ socioeconomic factors in rela-
tion to uptake of HPV vaccination in their seventh grade
daughters. In spite of the presumably equal access to
HPV vaccine in Norway, we found socioeconomic dispar-
ities in initiation of the HPV-vaccination series. Overall,
maternal income was positively associated with initiation
of HPV vaccination, whereas education was negatively
associated with initiation of HPV vaccination. Paternal
income and education showed similar, but weaker, asso-
ciations. The association with parental education was
restricted to girls with low-income parents. More than
94% of all girls who initiate the HPV-vaccination series
complete the schedule and receive all three doses as
recommended. Parental socioeconomic status had little
inﬂuence on completion of the three-dose series.
In our study, maternal income was associated with initi-
ation of HPV vaccination. Studies from publicly funded
school-based programmes in Scotland and Canada have
reported associations between deprivation and comple-
tion of the vaccination series in the routine programme,
but not with initiation.5 6 A study from England found
no association between deprivation and uptake of HPV
vaccine.4 However, the exposure measure in these
studies are hardly comparable to ours, as they have used
deprivation indices, made up of several dimensions of
deprivation and related to post code of residence, as
compared to the individual income data in our study.
The negative association observed between maternal
education level and initiation of HPV vaccination was
weak, but increased after adjustment. Our results are in
line with a Canadian study reporting decreased likeli-
hood of HPV vaccination with increasing parental edu-
cation level in a publicly funded school-based
programme.13 The opposite was, however, found in a
Swedish study of on-demand HPV vaccination.16
This inconsistency in ﬁndings could be explained by dif-
ferences in vaccine delivery systems, and may suggest
that highly educated parents make more active choices
on whether to vaccinate their daughters or not, as com-
pared to parents at lower education levels. Highly edu-
cated parents have earlier been reported to have more
negative attitudes towards vaccines in general than less
educated parents.17
Maternal education and income were more strongly
associated with initiation of HPV vaccination than pater-
nal education and income. This is in line with previous
Swedish results.16 We are, however, unable to draw con-
clusions on whether these ﬁndings reﬂect that under-
lying maternal factors in general are more important
than paternal in deciding about HPV vaccination based
on the data in our study.
Several factors, including maternal health-related
beliefs, attitudes and sociopsychological factors as well as
knowledge of HPV, safety concerns and media reports,
have been reported by others to be important determi-
nants for mothers’ decisions to vaccinate daughters
against HPV.13 18–20 Extensive media attention and
debate among central health ofﬁcials, disputing the
effectiveness and safety of the vaccine, preceded the
implementation of the HPV vaccination programme in
Norway.21–23 In addition to the inﬂuenza pandemic and
pandemic vaccination coinciding with the start of the
HPV vaccination programme, this public debate may be
a possible explanation why the uptake of HPV vaccine
was off to a low start in the ﬁrst vaccinated birth cohort.
The controversy was especially pronounced in the
county of Sør-Trøndelag,24 where the lowest uptake of
HPV vaccine was observed.25 One might also hypothesise
that this debate may have inﬂuenced the parental
opinion on HPV vaccination selectively. More highly
educated mothers may have followed the debate more
closely and thereby been more reluctant to vaccinate
their daughters than less educated mothers. However,
the current data set does not enable assessment of par-
ental beliefs or attitudes.
The negative association between maternal education
level and initiation of HPV vaccination was only seen
in daughters of mothers with income below median
value. This ﬁnding is hard to explain. However, we
speculate that highly educated mothers with low
incomes are more likely to work part-time than highly
educated mothers with high income. The same under-
lying factors may inﬂuence both the choice to work
part-time and the attitudes towards HPV vaccination.
We have no available data on part-time work in our
study population. However, about 30% of all
employed women in the age group 30–54 in Norway
are working part-time.26 Our results may suggest that
higher income mothers have a greater awareness of
cervical cancer or less scepticism about HPV vaccin-
ation than lower income mothers, regardless of edu-
cation level.
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The HPV vaccination programme in Norway is publicly
funded, and the vaccine is provided at school during
school hours. It was therefore surprising to ﬁnd that
maternal income was positively related to the uptake of
HPV vaccine. The inverse association between maternal
education level and initiation of HPV vaccination is also
interesting. There are generally limited wage differences
according to education level in Norway.27 This is reﬂected
in the moderate correlation we observed between educa-
tion and income (Spearman’s correlation coefﬁcient 0.47
and 0.41, for mothers and fathers, respectively). It seems
likely that different underlying mechanisms explain the
ﬁndings on education and income.
The observed associations between parental education
and income, and completion of the HPV vaccination, were
small and unlikely to be of clinical relevance. This may
indicate that factors important for completion of the
HPV vaccination series are different from those asso-
ciated with initiation. The proportion of girls completing
the vaccination series once they have started was,
however, high. Thus, to increase the overall uptake with
three doses, efforts should focus on increasing initiation
of HPV vaccination.
In this large data set we may detect statistically signiﬁ-
cant associations even for clinically insigniﬁcant differ-
ences. Hence, results should be interpreted with caution
and in relation to their public health relevance. Most of
the observed unadjusted differences in HPV vaccine
uptake between the socioeconomic groups were small.
However, the adjusted associations observed for maternal
education and income may, in our opinion, be consid-
ered meaningful in a public health perspective. A health
technology assessment recently performed by The
Norwegian Knowledge Centre for the Health Services
found that increasing the uptake of the ﬁrst dose of
HPV vaccine by 10 percentage points to the same level
as the other vaccines in the Childhood Immunisation
Programme in Norway, would result in an additional
reduction of between 3 and 4 cases of cervical cancer
and approximately 35 less cases of severe precancerous
cervical lesions yearly.28 In a Norwegian setting, with
about 300 cases of cervical cancer and approximately
3000 cases of severe precancerous cervical lesions
yearly,29 30 we ﬁnd this to be of clinical importance.
The major strength of our study is the use of individ-
ual data from different population-based registries, cov-
ering the total population. This allowed us to include all
girls eligible for HPV vaccination during the ﬁrst 3 years
of the HPV immunisation programme in Norway, limit-
ing selection bias while controlling for numerous pos-
sible confounders. The quality of the information on
vaccination in the Norwegian Immunisation Registry is
considered to be high, as there is mandatory notiﬁcation
to the immunisation registry. Moreover, extensive quality
assurance systems are implemented to secure the accur-
acy of the data.10 The statistics compiled and provided
by Statistics Norway are based on several nationwide
administrative registries. These data are widely used in
epidemiological research and are generally considered
to be of high quality. The information on immigrants’
education obtained abroad may, however, be less precise
as it is mainly based on surveys among immigrants.
The study is limited by incomplete information on
some of the variables that were included (mainly educa-
tion and income). The 7266 girls excluded due to
missing information were less likely to have initiated HPV
vaccination than the girls in the study sample (74.8% vs
78.3%, respectively). Moreover, a larger proportion of
them did not have Norway as country of origin, as com-
pared to the study sample (50.0% vs 7.8%, respectively).
However, sensitivity analyses where girls with missing
values were assigned values corresponding to the lowest
and highest parental education level, and income,
respectively, gave similar results. The effect estimates in
the sensitivity analysis did not differ from our results,
with more than 0.5 percentage points for any of the vari-
ables, with the exception of paternal education level,
where the difference in one of the sensitivity analyses
was 1.2 percentage points. Thus, it seems unlikely that
exclusion of girls with missing information has biased
the results.
CONCLUSION
In the current study, we observed inequalities in the
uptake of HPV vaccine related to socioeconomic factors
in the publicly funded school-based programme in
Norway. Maternal income was positively associated with
vaccine uptake in daughters. In contrast, maternal edu-
cation was negatively associated with HPV vaccination.
The ﬁndings were unexpected in a setting with presum-
ably equal access to HPV vaccination. More studies are
needed to explain the underlying factors responsible for
the observed socioeconomic differences in HPV vaccine
uptake. Insight into these factors is necessary in target-
ing information with the overall aim to increase vaccin-
ation coverage to the same high level as other childhood
vaccines, and to ultimately reduce HPV-related precan-
cerous lesion and cancers across socioeconomic barriers.
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